Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm atezolizumab study in PD-L1-positive advanced NSCLC
NL-OMON45051Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Objective response rate. Started Jul 2014; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45051.